[
  {
    "ts": null,
    "headline": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
    "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
    "url": "https://finnhub.io/api/news?id=0d74f9a697e32e7a858275c83749048028e8ce379b5ff188ab9702c77d3cab2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708780,
      "headline": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
      "id": 138000160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
      "url": "https://finnhub.io/api/news?id=0d74f9a697e32e7a858275c83749048028e8ce379b5ff188ab9702c77d3cab2a"
    }
  },
  {
    "ts": null,
    "headline": "OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate",
    "summary": "DALLAS, January 06, 2026--OncoNano Medicine, Inc. (\"OncoNano\") today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (\"Gilead\") to evaluate OncoNano’s ON-BOARD™ encapsulation technology with Gilead’s drug candidate.",
    "url": "https://finnhub.io/api/news?id=e99523aef85606176b999180816ae7d1fbad14d527121604f5a32353bdcaa15e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767700800,
      "headline": "OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate",
      "id": 137999416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "DALLAS, January 06, 2026--OncoNano Medicine, Inc. (\"OncoNano\") today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (\"Gilead\") to evaluate OncoNano’s ON-BOARD™ encapsulation technology with Gilead’s drug candidate.",
      "url": "https://finnhub.io/api/news?id=e99523aef85606176b999180816ae7d1fbad14d527121604f5a32353bdcaa15e"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
    "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
    "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767695400,
      "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
      "id": 137999357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
      "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?",
    "summary": "Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.",
    "url": "https://finnhub.io/api/news?id=99353f1e607ceea3f6a7fe3faa8d81b95dd762820e599e8c9cfcb3cef8b12085",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767672103,
      "headline": "Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?",
      "id": 138000629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.",
      "url": "https://finnhub.io/api/news?id=99353f1e607ceea3f6a7fe3faa8d81b95dd762820e599e8c9cfcb3cef8b12085"
    }
  }
]